TRAIL in cancer therapy: present and future challenges.

6533b7dafe1ef96bd126f6c3

RESEARCH PRODUCT

TRAIL in cancer therapy: present and future challenges.

Alexandre Morizot Olivier Micheau Eric Solary Delphine Merino Najoua Lalaoui

subject

MESH: Signal Transduction medicine.medical_treatment Clinical Biochemistry Apoptosis TRAIL TNF-Related Apoptosis-Inducing Ligand Bioinformatics TNF-Related Apoptosis-Inducing Ligand MESH : TNF-Related Apoptosis-Inducing Ligand 0302 clinical medicine Drug Delivery Systems Neoplasms Drug Discovery MESH: Animals MESH: Neoplasms 0303 health sciences Tnf superfamily 3. Good health MESH : Antineoplastic Agents Cytokine 030220 oncology & carcinogenesis Molecular Medicine MESH : Drug Delivery Systems TRAIL-Receptors.Signal transduction MESH: TNF-Related Apoptosis-Inducing Ligand Signal Transduction MESH: Forecasting Programmed cell death MESH: Drug Delivery Systems Cancer therapy Antineoplastic Agents Article resistance 03 medical and health sciences medicine [SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology Animals Humans cancer [SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology MESH : Forecasting TRAIL-receptor agonistic antibodies [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology 030304 developmental biology Pharmacology MESH : Signal Transduction MESH: Humans business.industry MESH: Apoptosis MESH : Humans Cancer medicine.disease MESH : Neoplasms Cancer cell Immunology MESH: Antineoplastic Agents MESH : Animals business TRAIL-Receptors MESH : Apoptosis Forecasting

description

International audience; Since its identification in 1995, TNF-related apoptosis-inducing ligand (TRAIL) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. In contrast to other members of the TNF superfamily, TRAIL administration in vivo is safe. The relative absence of toxic side effects of this naturally occurring cytokine, in addition to its antitumoural properties, has led to its preclinical evaluation. However, despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity or efficiency. An appropriate understanding of its physiological relevance, and of the mechanisms controlling cancer cells escape from TRAIL-induced cell death, will be required to optimally use the cytokine in clinics. The present review focuses on recent advances in the understanding of TRAIL signal transduction and discusses the existing and future challenges of TRAIL-based cancer therapy development.

year	journal	country	edition	language
2007-10-01

http://www.hal.inserm.fr/inserm-00527108/file/Review_Merino_TRAIL_EOTT_2007.pdf